Vertex Pharmaceuticals Incorporated entered into a definitive merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. through a wholly owned subsidiary, Clark Merger Sub, Inc. Under the terms of the agreement, Crinetics shareholders will receive $85.00 per share in cash. The transaction is expected to close in the third quarter of 2026, subject to stockholder approval and regulatory clearances. Vertex intends to finance the acquisition using cash on hand and new debt, supported by a $4.5 billion unsecured 364-day bridge loan facility provided by Bank of America, BofA Securities, and Morgan Stanley. Vertex Pharmaceuticals is a biotechnology company focused on developing medicines for serious diseases.